Application 208510
- Type
- NDA
- Sponsor
- SHIRE DEV LLC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | TABLET, CHEWABLE;ORAL | 10MG | Yes | No |
| 002 | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | TABLET, CHEWABLE;ORAL | 20MG | Yes | No |
| 003 | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | TABLET, CHEWABLE;ORAL | 30MG | Yes | No |
| 004 | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | TABLET, CHEWABLE;ORAL | 40MG | Yes | No |
| 005 | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | TABLET, CHEWABLE;ORAL | 50MG | Yes | No |
| 006 | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | TABLET, CHEWABLE;ORAL | 60MG | Yes | Yes |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N208510-001 | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 10MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 |
| N208510-002 | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 20MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 |
| N208510-003 | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 30MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 |
| N208510-004 | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 40MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 |
| N208510-005 | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 50MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 |
| N208510-006 | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 60MG | TABLET, CHEWABLE / ORAL | AB | RLD, RS | 2017-01-28 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N208510-001 | AB |
| N208510-002 | AB |
| N208510-003 | AB |
| N208510-004 | AB |
| N208510-005 | AB |
| N208510-006 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | N208510-001 | VYVANSE | 10MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208510-002 | VYVANSE | 20MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208510-003 | VYVANSE | 30MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208510-004 | VYVANSE | 40MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208510-005 | VYVANSE | 50MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208510-006 | VYVANSE | 60MG | TABLET, CHEWABLE / ORAL | AB | RLD, RS | 2017-01-28 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208510-001 | VYVANSE | 10MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208510-002 | VYVANSE | 20MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208510-003 | VYVANSE | 30MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208510-004 | VYVANSE | 40MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208510-005 | VYVANSE | 50MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208510-006 | VYVANSE | 60MG | TABLET, CHEWABLE / ORAL | AB | RLD, RS | 2017-01-28 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N208510-001 | VYVANSE | 10MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N208510-002 | VYVANSE | 20MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N208510-003 | VYVANSE | 30MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N208510-004 | VYVANSE | 40MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N208510-005 | VYVANSE | 50MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N208510-006 | VYVANSE | 60MG | TABLET, CHEWABLE / ORAL | AB | RLD, RS | 2017-01-28 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208510-001 | VYVANSE | 10MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208510-002 | VYVANSE | 20MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208510-003 | VYVANSE | 30MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208510-004 | VYVANSE | 40MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208510-005 | VYVANSE | 50MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208510-006 | VYVANSE | 60MG | TABLET, CHEWABLE / ORAL | AB | RLD, RS | 2017-01-28 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208510-001 | VYVANSE | 10MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208510-002 | VYVANSE | 20MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208510-003 | VYVANSE | 30MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208510-004 | VYVANSE | 40MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208510-005 | VYVANSE | 50MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208510-006 | VYVANSE | 60MG | TABLET, CHEWABLE / ORAL | AB | RLD, RS | 2017-01-28 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208510-001 | VYVANSE | 10MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208510-002 | VYVANSE | 20MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208510-003 | VYVANSE | 30MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208510-004 | VYVANSE | 40MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208510-005 | VYVANSE | 50MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208510-006 | VYVANSE | 60MG | TABLET, CHEWABLE / ORAL | AB | RLD, RS | 2017-01-28 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N208510-001 | VYVANSE | 10MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N208510-002 | VYVANSE | 20MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N208510-003 | VYVANSE | 30MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N208510-004 | VYVANSE | 40MG | TABLET, CHEWABLE / ORAL | AB | RLD | 2017-01-28 | 2680178bc6a6… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | N208510-001 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208510-002 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208510-003 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208510-004 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208510-005 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208510-006 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208510-001 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208510-002 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208510-003 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208510-004 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208510-005 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208510-006 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N208510-001 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N208510-002 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N208510-003 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N208510-004 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N208510-005 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N208510-006 | AB | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208510-001 | AB | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208510-002 | AB | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208510-003 | AB | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208510-004 | AB | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208510-005 | AB | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208510-006 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208510-001 | AB | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208510-002 | AB | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208510-003 | AB | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208510-004 | AB | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208510-005 | AB | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208510-006 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208510-001 | AB | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208510-002 | AB | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208510-003 | AB | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208510-004 | AB | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208510-005 | AB | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208510-006 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N208510-001 | AB | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N208510-002 | AB | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N208510-003 | AB | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N208510-004 | AB | 1 | 2680178bc6a6… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7105486 | 2023-02-24 | U-727 | 2017-02-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7223735 | 2023-02-24 | Drug product | 2017-02-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7655630 | 2023-02-24 | Drug substance, Drug product | 2017-02-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7659253 | 2023-02-24 | U-727 | Drug substance, Drug product | 2017-02-27 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7659254 | 2023-02-24 | U-727 | 2017-02-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7662787 | 2023-02-24 | Drug substance | 2017-02-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7662788 | 2023-02-24 | U-727 | 2017-02-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7671030 | 2023-02-24 | U-727 | Drug product | 2017-02-27 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7671031 | 2023-02-24 | U-727 | 2017-02-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7674774 | 2023-02-24 | U-727 | Drug product | 2017-02-27 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7678770 | 2023-02-24 | U-727 | 2017-02-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7678771 | 2023-02-24 | U-727 | Drug product | 2017-02-27 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7687466 | 2023-02-24 | Drug product | 2017-02-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7687467 | 2023-02-24 | U-727 | Drug product | 2017-02-27 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7713936 | 2023-02-24 | U-727 | 2017-02-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7718619 | 2023-02-24 | U-727 | Drug product | 2017-02-27 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7723305 | 2023-02-24 | U-727 | Drug product | 2017-02-27 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7105486*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7223735*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7655630*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7659253*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7659254*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7662787*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7662788*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7671030*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7671031*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7674774*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7678770*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7678771*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7687466*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7687467*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7713936*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7718619*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-001 | 7723305*PED | 2023-08-24 | Pediatric extension | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-002 | 7105486 | 2023-02-24 | U-727 | 2017-02-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-002 | 7223735 | 2023-02-24 | Drug product | 2017-02-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-002 | 7655630 | 2023-02-24 | Drug substance, Drug product | 2017-02-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-002 | 7659253 | 2023-02-24 | U-727 | Drug substance, Drug product | 2017-02-27 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-002 | 7659254 | 2023-02-24 | U-727 | 2017-02-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208510-002 | 7662787 | 2023-02-24 | Drug substance | 2017-02-27 | 5c6f7cd8ea54… |
Observed Orange Book exclusivity history#
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | N208510-001 | M-188 | 2019-10-14 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N208510-002 | M-188 | 2019-10-14 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N208510-003 | M-188 | 2019-10-14 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N208510-004 | M-188 | 2019-10-14 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N208510-005 | M-188 | 2019-10-14 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N208510-006 | M-188 | 2019-10-14 | 74a2ff9319b5… |
| 2019-12-14 00:12 UTC | 2019-12 | N208510-001 | M-188 | 2019-10-14 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | N208510-002 | M-188 | 2019-10-14 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | N208510-003 | M-188 | 2019-10-14 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | N208510-004 | M-188 | 2019-10-14 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | N208510-005 | M-188 | 2019-10-14 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | N208510-006 | M-188 | 2019-10-14 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N208510-001 | M-188 | 2019-10-14 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N208510-002 | M-188 | 2019-10-14 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N208510-003 | M-188 | 2019-10-14 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N208510-004 | M-188 | 2019-10-14 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N208510-005 | M-188 | 2019-10-14 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N208510-006 | M-188 | 2019-10-14 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N208510-001 | M-188 | 2019-10-14 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N208510-002 | M-188 | 2019-10-14 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N208510-003 | M-188 | 2019-10-14 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N208510-004 | M-188 | 2019-10-14 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N208510-005 | M-188 | 2019-10-14 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N208510-006 | M-188 | 2019-10-14 | ea99ee380514… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | 704e4378-ca83-445c-8b45-3cfa51c1ecad | 2026-04-30 | Boxed warning, Warnings, Adverse reactions | 208510 NDA208510 59417-119 59417-116 59417-117 59417-118 59417-115 59417-120 |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 59417-115 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-115 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-115 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-115 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Shire LLC | NDA | Current |
| 59417-115 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-115 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Shire LLC | NDA | Current |
| 59417-116 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-116 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-116 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-116 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Shire LLC | NDA | Current |
| 59417-116 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-116 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Shire LLC | NDA | Current |
| 59417-117 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-117 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-117 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-117 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Shire LLC | NDA | Current |
| 59417-117 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-117 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Shire LLC | NDA | Current |
| 59417-118 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-118 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-118 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-118 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Shire LLC | NDA | Current |
| 59417-118 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-118 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Shire LLC | NDA | Current |
| 59417-119 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-119 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-119 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-119 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Shire LLC | NDA | Current |
| 59417-119 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-119 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Shire LLC | NDA | Current |
| 59417-120 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-120 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-120 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-120 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Shire LLC | NDA | Current |
| 59417-120 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Takeda Pharmaceuticals America, Inc. | NDA | Current |
| 59417-120 | Vyvanse | LISDEXAMFETAMINE DIMESYLATE | Shire LLC | NDA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 85758 | SUPPL | 2026-04-27 |
| 85803 | SUPPL | 2026-04-24 |
| 85750 | SUPPL | 2026-04-24 |
| 83521 | SUPPL | 2025-09-25 |
| 83520 | SUPPL | 2025-09-25 |
| 83445 | SUPPL | 2025-09-25 |
| 75774 | SUPPL | 2023-10-16 |
| 75742 | SUPPL | 2023-10-16 |
| 70335 | SUPPL | 2022-03-01 |
| 70334 | SUPPL | 2022-03-01 |
| 70302 | SUPPL | 2022-02-28 |
| 69220 | SUPPL | 2021-11-03 |
| 69219 | SUPPL | 2021-11-03 |
| 69215 | SUPPL | 2021-11-03 |
| 68234 | SUPPL | 2021-08-02 |
| 68230 | SUPPL | 2021-07-30 |
| 68229 | SUPPL | 2021-07-30 |
| 50056 | ORIG | 2017-10-13 |
| 49199 | SUPPL | 2017-08-02 |
| 49176 | SUPPL | 2017-08-01 |
| 49175 | SUPPL | 2017-08-01 |
| 48499 | SUPPL | 2017-05-23 |
| 48489 | SUPPL | 2017-05-23 |
| 47073 | ORIG | 2017-01-31 |
| 47037 | ORIG | 2017-01-27 |
| 51313 | ORIG | 1900-01-01 |
| 51312 | ORIG | 1900-01-01 |